An evaluation of the efficacy of Dermeton on proliferation of Scleroderma.
An in-house study by The Gordon's Herbal Research Center (GHRC)

Experiments were performed in our research center to study the effects of Dermeton on the containment of Scleroderma. Dermeton was administered orally through pill form to the sample group of patients.

Twenty data points for each treatment were collected and evaluated using statistical methods to compare the treatment progress.

Data indicates that Dermeton is efficacious in the treatment of Scleroderma. These preliminary laboratory studies and histological evaluation of patients treated with Dermeton indicate that the compound inhibits the progress of the disease and further research should be conducted for confirmation.

Another controlled study to test the efficacy of Dermeton for Scleroderma.
Dermeton has been developed for the treatment of Scleroderma.

In a preliminary controlled study, Dermeton has been administered orally in pill form in set group of patients.

Results were obtained for 200 patients . All had previous treatments of various natures.

The results from these treatments consisted of symptomatic relief.

None of the patients were receiving any oral or topical medications at the time of the Dermeton treatment.

Treatment with Dermeton was continued until two weeks in addition to the time of complete disappearance of symptoms.

The treatment periods ranged from four to twelve weeks.

Follow-ups after treatment ranged from seven months to three years and showed resolution of Scleroderma with no clinical recurrences.

Here is a summary of the clinical trail conducted in compliance
with the protocol, cGCP, applicable regulatory requirements:

The extensive report includes over 300 pages and is 18 megabytes in size. The trials were a success.
The study concludes that 72 percent of patients experienced an improvement of 1 or more on the Physician’s Global Assessment (PGA).
53 percent of users saw a Physician’s Global Assessment (PGA) reduction of 2 or more.
17 percent saw a reduction of 3 or more.
67 percent of patients who started with a PGA of 4 (the most severe in the patient population) experienced an improvement of 2 or more.
89 percent of patients who started with a PGA of 4 (the most severe) experienced an improvement of 1 or more on a scale of 5 in the PGA.
91 percent of the patents started the study with a condition classified as “deteriorating.”
100 percent of the patients tested experienced no side effects while using Dermeton.
Based on this data it is believed that if the medication protocol treatment period was longer, the results would have been even better.
The clinical trials on Dermeton were conducted under the regulations of FDA and New Zealand health authority.